Rohit Katial
A5075773797- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Drug-Induced Adverse Reactions
- Sinusitis and nasal conditions
- Food Allergy and Anaphylaxis Research
- IL-33, ST2, and ILC Pathways
- Urticaria and Related Conditions
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Disorders and Syndromes
- Dermatology and Skin Diseases
- Contact Dermatitis and Allergies
- Monoclonal and Polyclonal Antibodies Research
- Delphi Technique in Research
- Mast cells and histamine
- Inflammatory mediators and NSAID effects
- Tuberculosis Research and Epidemiology
- Occupational exposure and asthma
- Neuroscience of respiration and sleep
- Nasal Surgery and Airway Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
National Jewish Health
2015-2025
University of Colorado Denver
2015-2025
Clinical Trials New Zealand
2024-2025
AstraZeneca (United States)
2020-2024
Tauranga Hospital
2024
Suzhou Municipal Hospital
2024
AstraZeneca (Brazil)
2023
AstraZeneca (Italy)
2023
Denver School of Nursing
2016-2020
Research Triangle Park Foundation
2018
Consensus definitions for clinical remission and super-response were recently established severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody severe, uncontrolled asthma; efficacy safety demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite definition to characterize individual responses benralizumab after 6 12 months. In studies, eligible patients those with asthma receiving medium- or...
Rationale: There is no consensus on criteria to include in an asthma remission definition real-life. Factors associated with achieving post-biologic-initiation remain poorly understood. Objectives: To quantify the proportion of adults severe multi-domain-defined and identify pre-biologic characteristics which may be used predict it. Methods: This was a longitudinal cohort study using data from 23 countries International Severe Asthma Registry. Four outcome domains were assessed 1-year pre-...
Background Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its effectiveness SEA according previous biologic use key baseline characteristics important for treatment selection. Methods XALOC-1 is a large, multinational, retrospective, observational, study programme of benralizumab adults with SEA. This 48-week integrated analysis assessed annualised...
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As first global registry for adults with asthma, ISAR enabled individual registries standardize pool their data, creating a comprehensive, harmonized dataset sufficient statistical power address key research questions knowledge gaps. Today, is largest repository real-world data on curating nearly 35,000 patients...
BackgroundDupilumab, an anti–IL-4 receptor α mAb, inhibits IL-4/IL-13 signaling, key drivers of type 2/TH2 immune diseases (eg, atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality life, was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2-agonists.ObjectiveTo examine dupilumab's effect on the 22-item...
Previous studies investigating the impact of comorbidities on effectiveness biologic agents have been relatively small and short duration not compared classes agents.
BackgroundInvestigation for the presence of asthma comorbidities is recommended by GINA as their can complicate management.ObjectiveTo understand prevalence and pattern multimorbidity in adults with severe association asthma-related outcomes.MethodsThis was a cross-sectional study using data from International Severe Asthma Registry 22 countries. Thirty were identified categorized priori either (1) potentially T2-related, (2) oral corticosteroid (OCS)-related or (3) mimicking/aggravating...
Background To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers assessment of biologic efficacy from structured clinical trials. Aim elucidate associations individual or their combinations with pre-to-post changes in asthma real-life. Methods This was a registry-based, cohort study using data 23 countries, which shared International Severe Asthma Registry (May 2017-February 2023). The...
What is already known about the topic? Response to biologics variable, partly due inclusion of different outcomes in response definitions (e.g. exacerbations, long-term corticosteroid dose, symptom control, lung function). Identifying those most likely respond real-life has proven challenging. does this article add our knowledge? and their predictors vary according outcome assessed. A greater pre-biologic impairment associated with better for all However shorter asthma duration function...
BackgroundReal-world evidence characterizing the clinical outcomes and economic impact on patients with severe eosinophilic asthma treated benralizumab is limited.ObjectiveTo characterize assess its in United States.MethodsA pre-post comparison was performed using a large US insurance claims database between November 2016 2019. The primary cohort included aged 12 years or more 2 records of benralizumab. Secondary cohorts persistent users (6 benralizumab), switching to from mepolizumab...
Purpose: Real-world evidence of benralizumab effectiveness on nasal polyps (NP) and asthma outcomes in patients with severe eosinophilic (SEA) comorbid chronic rhinosinusitis NP are limited. The objective this study was to assess benralizumab-treated SEA a real-world setting. Patients Methods: RANS retrospective, multi-country observational (ClinicalTrials.gov: NCT05180357) using medical chart reviews adults NP. Total Score (NPS), SinoNasal Outcome Test-22 (SNOT-22) total score, annualized...